Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis - PubMed (original) (raw)

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

B Y Tung et al. Ann Intern Med. 2001.

Abstract

Background: Patients with ulcerative colitis and primary sclerosing cholangitis are at high risk for colonic dysplasia and cancer. This risk approaches 50% after 25 years of colitis. Ursodiol has been shown to protect against development of colorectal neoplasia in animal models.

Objective: To assess the relationship between ursodiol use and colonic dysplasia, the precursor to colon cancer, in patients with ulcerative colitis and primary sclerosing cholangitis.

Design: Cross-sectional study.

Setting: University medical center.

Patients: 59 patients with ulcerative colitis and primary sclerosing cholangitis who were undergoing colonoscopic surveillance for colonic dysplasia.

Measurements: Use of ursodiol was assessed in all patients. The presence or absence of colonic dysplasia was evaluated by colonoscopic surveillance. Other variables assessed were age at onset and duration of ulcerative colitis; duration of primary sclerosing cholangitis; Child-Pugh classification; and use of sulfasalazine, other 5-aminosalicylic acid preparations, prednisone, cyclosporine, azathioprine, and methotrexate.

Results: Ursodiol use was strongly associated with decreased prevalence of colonic dysplasia (odds ratio, 0.18 [95% CI, 0.05 to 0.61]; P = 0.005). The association between dysplasia and ursodiol use remained after adjustment for sex, age at onset of colitis, duration of colitis, duration of sclerosing cholangitis, severity of liver disease, and sulfasalazine use (adjusted odds ratio, 0.14 [CI, 0.03 to 0.64]; P = 0.01). Younger age at onset of colitis was associated with an increased risk for dysplasia.

Conclusions: Ursodiol use appears to be associated with a lower frequency of colonic dysplasia in patients with ulcerative colitis and primary sclerosing cholangitis. A randomized trial investigating the chemoprotective effect of ursodiol in patients with ulcerative colitis may be warranted.

PubMed Disclaimer

Comment in

Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research.
Hawk ET, Viner JL. Hawk ET, et al. Ann Intern Med. 2001 Jan 16;134(2):158-60. doi: 10.7326/0003-4819-134-2-200101160-00017. Ann Intern Med. 2001. PMID: 11177320 No abstract available.

Cited by

Therapeutic role of ursodeoxycholic acid in colitis-associated cancer via gut microbiota modulation.
He Q, Wu J, Ke J, Zhang Q, Zeng W, Luo Z, Gong J, Chen Y, He Z, Lan P. He Q, et al. Mol Ther. 2023 Feb 1;31(2):585-598. doi: 10.1016/j.ymthe.2022.10.014. Epub 2022 Oct 29. Mol Ther. 2023. PMID: 38556635 Free PMC article.
Preventive effects of 13 different drugs on colorectal cancer: a network meta-analysis.
Fu Q, Liao H, Li Z, Chen X, Zhang X, Di J. Fu Q, et al. Arch Med Sci. 2023 Jun 21;19(5):1428-1445. doi: 10.5114/aoms/167480. eCollection 2023. Arch Med Sci. 2023. PMID: 37732038 Free PMC article. Review.
Inflammation in the proximal colon is a risk factor for the development of colorectal neoplasia in inflammatory bowel disease patients with primary sclerosing cholangitis.
Jamil OK, Shaw D, Deng Z, Dinardi N, Fillman N, Khanna S, Krugliak Cleveland N, Sakuraba A, Weber CR, Cohen RD, Dalal S, Jabri B, Rubin DT, Pekow J. Jamil OK, et al. Therap Adv Gastroenterol. 2023 Sep 7;16:17562848231184985. doi: 10.1177/17562848231184985. eCollection 2023. Therap Adv Gastroenterol. 2023. PMID: 37692199 Free PMC article.
Current Therapeutics in Primary Sclerosing Cholangitis.
Tan N, Lubel J, Kemp W, Roberts S, Majeed A. Tan N, et al. J Clin Transl Hepatol. 2023 Oct 28;11(5):1267-1281. doi: 10.14218/JCTH.2022.00068S. Epub 2023 Apr 17. J Clin Transl Hepatol. 2023. PMID: 37577219 Free PMC article. Review.
Current Therapies for Cholestatic Diseases.
Méndez-Sánchez N, Coronel-Castillo CE, Ordoñez-Vázquez AL. Méndez-Sánchez N, et al. Biomedicines. 2023 Jun 15;11(6):1713. doi: 10.3390/biomedicines11061713. Biomedicines. 2023. PMID: 37371808 Free PMC article. Review.

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis - PubMed (original) (raw)